

# Consuelo Buttigliero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3773165/publications.pdf>

Version: 2024-02-01

60  
papers

1,395  
citations

361413

20  
h-index

361022

35  
g-index

60  
all docs

60  
docs citations

60  
times ranked

2550  
citing authors

#	ARTICLE	IF	CITATIONS
1	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1250-1264.	10.7	159
2	Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 884-892.	7.7	141
3	Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 563-573.	1.9	101
4	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015, 68, 147-153.	1.9	73
5	Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7353-7368.	2.0	58
6	Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 44, 61-73.	7.7	56
7	Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. <i>European Urology</i> , 2022, 81, 274-282.	1.9	55
8	Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 124-133.	1.1	52
9	Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. <i>Oncotarget</i> , 2015, 6, 12520-12528.	1.8	47
10	Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases. <i>Human Pathology</i> , 2015, 46, 1799-1807.	2.0	44
11	Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. <i>Cancer Treatment Reviews</i> , 2017, 54, 1-9.	7.7	44
12	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 70, 67-74.	7.7	41
13	Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103185.	4.4	41
14	TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)â€”First interim analysis (IA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 119-119.	1.6	31
15	Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. <i>Cancer Treatment Reviews</i> , 2019, 74, 35-42.	7.7	30
16	Hormonal treatment and quality of life of prostate cancer patients: new evidence. <i>Minerva Urology and Nephrology</i> , 2018, 70, 144-151.	2.5	25
17	Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 613-613.	1.6	25
18	Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. <i>Acta OncolÃ³gica</i> , 2017, 56, 555-562.	1.8	24

#	ARTICLE	IF	CITATIONS
19	Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer. <i>Oncotarget</i> , 2016, 7, 14394-14404.	1.8	23
20	Androgen deprivation modulates gene expression profile along prostate cancer progression. <i>Human Pathology</i> , 2016, 56, 81-88.	2.0	20
21	Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. <i>Cancer Treatment Reviews</i> , 2018, 69, 215-223.	7.7	19
22	Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. <i>Cells</i> , 2022, 11, 803.	4.1	19
23	The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome. <i>Endocrine</i> , 2015, 50, 223-230.	2.3	18
24	Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 124-132.	4.4	18
25	Prostate cancer management at an Italian tertiary referral center: does multidisciplinary team meeting influence diagnostic and therapeutic decision-making process? A snapshot of the everyday clinical practice. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 576-582.	3.9	16
26	New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond. <i>Cells</i> , 2022, 11, 357.	4.1	16
27	Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma. <i>Endocrine Pathology</i> , 2017, 28, 95-102.	9.0	15
28	TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRM) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5566-5566.	1.6	15
29	Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. <i>Endocrine-Related Cancer</i> , 2021, 28, R207-R216.	3.1	14
30	Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 610-627.	2.8	13
31	Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R1-R9.	3.1	13
32	Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102994.	4.4	13
33	Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, e251-e259.	3.7	11
34	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. <i>BioMed Research International</i> , 2017, 2017, 1-13.	1.9	10
35	Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 332-347.e2.	1.9	9
36	Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2019, 15, 1115-1123.	2.4	9

#	ARTICLE	IF	CITATIONS
37	Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review. <i>Cancers</i> , 2020, 12, 2568.	3.7	8
38	The prognostic value of pain in castration-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 654-660.	3.9	7
39	Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. , 2020, 3, 726-741.		6
40	Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 737-745.	3.9	6
41	Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents. <i>Endocrine</i> , 2019, 64, 724-726.	2.3	5
42	Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 812-825.	3.9	5
43	New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103682.	4.4	5
44	Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1087-e1090.	1.9	4
45	Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 318-324.	1.9	4
46	Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report. <i>Tumori</i> , 2021, 107, NP149-NP154.	1.1	4
47	Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. <i>Minerva Urology and Nephrology</i> , 2022, 73, .	2.5	4
48	Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. <i>European Journal of Cancer</i> , 2021, 155, 127-135.	2.8	3
49	Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016.. <i>Journal of Clinical Oncology</i> , 2019, 37, 219-219.	1.6	3
50	Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough?. <i>Minerva Urology and Nephrology</i> , 2022, 73, 870-872.	2.5	3
51	Prognostic factors in metastatic castration resistant prostate cancer patients treated with Radium-223: a retrospective study. <i>Minerva Urology and Nephrology</i> , 2022, , .	2.5	2
52	First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 439-439.	1.6	2
53	Immediate or Delayed Nephrectomy in Patients With Metastatic Renal Cancer Who Are Receiving Targeted Agents: Is the Analysis at Risk for Guarantee-Time Bias?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1264-1264.	1.6	1
54	Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5047-5047.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Programmed death ligand-1 (PD-L1) expression in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in NIVES study.. Journal of Clinical Oncology, 2021, 39, 4558-4558.	1.6	1
56	Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).. Journal of Clinical Oncology, 2020, 38, TPS762-TPS762.	1.6	1
57	Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis. Tumori, 2022, , 030089162210771.	1.1	1
58	Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?. Cells, 2022, 11, 1614.	4.1	1
59	Zoledronic Acid Dosing Interval for Metastatic Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1477.	7.4	0
60	Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.. Journal of Clinical Oncology, 2020, 38, TPS596-TPS596.	1.6	0